Effects of Cannabidiol, Hypothermia, and Their Combination in Newborn Rats with Hypoxic-Ischemic Encephalopathy.
cannabidiol
hypothermia
hypoxic-ischemic encephalopathy
juvenile
neonate
neuroprotection
Journal
eNeuro
ISSN: 2373-2822
Titre abrégé: eNeuro
Pays: United States
ID NLM: 101647362
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
07
10
2022
revised:
29
03
2023
accepted:
07
04
2023
medline:
8
5
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
epublish
Résumé
Therapeutic hypothermia is well established as a standard treatment for infants with hypoxic-ischemic (HI) encephalopathy but it is only partially effective. The potential for combination treatments to augment hypothermic neuroprotection has major relevance. Our aim was to assess the effects of treating newborn rats following HI injury with cannabidiol (CBD) at 0.1 or 1 mg/kg, i.p., in normothermic (37.5°C) and hypothermic (32.0°C) conditions, from 7 d of age (neonatal phase) to 37 d of age (juvenile phase). Placebo or CBD was administered at 0.5, 24, and 48 h after HI injury. Two sensorimotor (rotarod and cylinder rearing) and two cognitive (novel object recognition and T-maze) tests were conducted 30 d after HI. The extent of brain damage was determined by magnetic resonance imaging, histologic evaluation, magnetic resonance spectroscopy, amplitude-integrated electroencephalography, and Western blotting. At 37 d, the HI insult produced impairments in all neurobehavioral scores (cognitive and sensorimotor tests), brain activity (electroencephalography), neuropathological score (temporoparietal cortexes and CA1 layer of hippocampus), lesion volume, magnetic resonance biomarkers of brain injury (metabolic dysfunction, excitotoxicity, neural damage, and mitochondrial impairment), oxidative stress, and inflammation (TNFα). We observed that CBD or hypothermia (to a lesser extent than CBD) alone improved cognitive and motor functions, as well as brain activity. When used together, CBD and hypothermia ameliorated brain excitotoxicity, oxidative stress, and inflammation, reduced brain infarct volume, lessened the extent of histologic damage, and demonstrated additivity in some parameters. Thus, coadministration of CBD and hypothermia could complement each other in their specific mechanisms to provide neuroprotection.
Identifiants
pubmed: 37072177
pii: ENEURO.0417-22.2023
doi: 10.1523/ENEURO.0417-22.2023
pmc: PMC10166126
pii:
doi:
Substances chimiques
Cannabidiol
19GBJ60SN5
Neuroprotective Agents
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Alvarez et al.
Déclaration de conflit d'intérêts
F.J.A. has a research agreement with GW Research Ltd, which is now a part of Jazz Pharmaceuticals, from which he receives financial support. W.H. is an employee Jazz Pharmaceuticals. The authors declare no other competing financial interests.
Références
PLoS One. 2018 Jul 3;13(7):e0199890
pubmed: 29969470
Exp Brain Res. 2008 Mar;185(4):595-601
pubmed: 17989968
Cochrane Database Syst Rev. 2003;(4):CD003311
pubmed: 14583966
Neuropharmacology. 2019 Mar 1;146:1-11
pubmed: 30468796
Neuropharmacology. 2013 Aug;71:282-91
pubmed: 23587650
CNS Neurol Disord Drug Targets. 2017;16(1):102-108
pubmed: 27686886
Cogn Process. 2012 May;13(2):93-110
pubmed: 22160349
Free Radic Biol Med. 2009 Jun 1;46(11):1472-7
pubmed: 19272443
Pediatr Res. 2009 Jan;65(1):62-6
pubmed: 18724268
Pediatr Res. 2010 Oct;68(4):303-8
pubmed: 20606598
Neuroscience. 2015 Aug 27;302:174-203
pubmed: 25242643
Environ Res. 2009 Nov;109(8):1021-7
pubmed: 19762015
Int J Dev Neurosci. 2008 Feb;26(1):67-76
pubmed: 17950559
Dis Markers. 2020 Sep 23;2020:8850816
pubmed: 33029259
Front Pediatr. 2023 Jan 27;11:1070743
pubmed: 36776908
J Neurophysiol. 2013 Feb;109(3):900-11
pubmed: 23114207
Pediatrics. 2011 May;127(5):e1280-7
pubmed: 21482614
Br J Pharmacol. 2015 Apr;172(7):1783-91
pubmed: 25425111
Arch Dis Child Fetal Neonatal Ed. 1996 Jan;74(1):F3-9
pubmed: 8653432
Pharmacol Biochem Behav. 2019 Sep;184:172741
pubmed: 31336109
Pediatr Res. 2016 Nov;80(5):710-718
pubmed: 27441365
Stroke. 2008 Apr;39(4):1307-13
pubmed: 18309163
BMJ. 2010 Feb 09;340:c363
pubmed: 20144981
Neurotherapeutics. 2015 Oct;12(4):699-730
pubmed: 26264914
Front Neurosci. 2016 Jul 12;10:323
pubmed: 27462203
Pediatr Res. 2007 Sep;62(3):255-60
pubmed: 17622949
Lancet Neurol. 2011 Apr;10(4):372-82
pubmed: 21435600
Dev Neurosci. 2003 Nov-Dec;25(6):394-402
pubmed: 14966380
Pediatr Res. 2008 Dec;64(6):653-8
pubmed: 18679164
Clin Perinatol. 2014 Mar;41(1):119-31
pubmed: 24524450
Neuropharmacology. 2012 Oct;63(5):776-83
pubmed: 22659086
Neonatology. 2017;112(2):143-149
pubmed: 28564654
Int J Mol Sci. 2018 Mar 13;19(3):
pubmed: 29533978
Neuropharmacology. 2017 Apr;116:151-159
pubmed: 28012949
Ann N Y Acad Sci. 2010 Jun;1199:164-74
pubmed: 20633122
Pediatr Res. 2011 Sep;70(3):272-7
pubmed: 21654550
Pediatr Res. 2002 Mar;51(3):354-60
pubmed: 11861942
Learn Mem. 2009 Dec 22;17(1):5-11
pubmed: 20028732
Clin Perinatol. 2014 Mar;41(1):161-75
pubmed: 24524453
Neurochem Res. 2019 Nov;44(11):2631-2642
pubmed: 31564017
Neurosci Biobehav Rev. 2007;31(5):673-704
pubmed: 17368764
Pathophysiology. 2003 Dec;10(1):7-35
pubmed: 14643901
Front Pharmacol. 2021 Jan 11;11:584533
pubmed: 33505306
Pediatr Res. 2015 Sep;78(3):264-71
pubmed: 25996893
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Nat Protoc. 2006;1(1):7-12
pubmed: 17406205
Neurobiol Dis. 2010 Feb;37(2):434-40
pubmed: 19900555
Neonatology. 2017;112(1):67-72
pubmed: 28351039
J Neurosci Methods. 2006 Dec 15;158(2):219-23
pubmed: 16837051
Biochim Biophys Acta. 2011 Apr;1813(4):508-20
pubmed: 21146563
Interdiscip Toxicol. 2008 Dec;1(3-4):206-10
pubmed: 21218116